Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Molecules ; 27(5)2022 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-35268807

RESUMO

Oxytropis falcata Bunge is a plant used in traditional Tibetan medicine, with reported anti-inflammatory and antioxidants effects and alleviation of myocardial ischemia reperfusion injury (MIRI). However, the underlying mechanism against MIRI and the phytochemical composition of O. falcata are vague. One fraction named OFF1 with anti-MIRI activity was obtained from O. falcata, and the chemical constituents were identified by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS). The potential targets and signaling pathways involved in the action of O. falcata against MIRI were predicted by network pharmacology analysis, and its molecular mechanism on MIRI was determined by in vitro assays. The results revealed that flavonoids are the dominant constituents of OFF1. A total of 92 flavonoids reported in O. falcata targeted 213 potential MIRI-associated factors, including tumor necrosis factor (TNF), prostaglandin-endoperoxide synthase 2 (PTGS2), and the NF-κB signaling pathway. The in vitro assay on H9c2 cardiomyocytes subjected to hypoxia/reoxygenation injury confirmed that the flavonoids in OFF1 reduced myocardial marker levels, apoptotic rate, and the inflammatory response triggered by oxidative stress. Moreover, OFF1 attenuated MIRI by downregulating the ROS-mediated JNK/p38MAPK/NF-κB pathway. Collectively, these findings provide novel insights into the molecular mechanism of O. falcata in alleviating MIRI, being a potential therapeutic candidate.


Assuntos
Traumatismo por Reperfusão Miocárdica , Oxytropis , Flavonoides/farmacologia , Flavonoides/uso terapêutico , Traumatismo por Reperfusão Miocárdica/metabolismo , NF-kappa B/metabolismo , Oxytropis/química , Transdução de Sinais
2.
Biotechnol Lett ; 29(6): 885-9, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17415532

RESUMO

A bioconversion process of producing GM1 (monosialotetrahexosylganglioside) on an industrial scale was developed with a novel sialidase-producing strain Brevibacterium casei. The sialidase hydrolyzed polysialogangliosides to produce GM1 but did not act on GM1. When Brevibacterium casei was cultured in a synthetic medium containing crude pig brain gangliosides (10% w/v) at 30 degrees C for 24 h in a 50 l fermenter, most of the polysialogangliosides were converted to GM1. The content of GM1 was increased from 9% in crude gangliosides to 45% with 70% (w/w) yield.


Assuntos
Brevibacterium/metabolismo , Gangliosídeos/metabolismo , Neuraminidase/metabolismo , Animais , Encéfalo/metabolismo , Brevibacterium/enzimologia , Cromatografia em Camada Fina , Gangliosídeos/química , Concentração de Íons de Hidrogênio , Cinética , Especificidade por Substrato , Suínos , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA